Skip to content
Evigrade
CriticalClass III antiarrhythmic, selective IKr blocker×Non-selective beta blocker with class III antiarrhythmic activity

Updated · Methodology

Mechanism

Sotalol, a beta-blocker with class III antiarrhythmic properties, prolongs the cardiac action potential and the QT interval and can cause torsade de pointes (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is a class III antiarrhythmic that blocks the rapid component of the delayed rectifier potassium current (IKr). QT prolongation depends directly on its plasma concentration, and dofetilide can also cause serious ventricular arrhythmias, mainly torsade de pointes (dofetilide label, US Food and Drug Administration, FDA). The Spanish sotalol SmPC names dofetilide among the class III antiarrhythmics that induce torsade de pointes and raise the risk of ventricular arrhythmias when given with sotalol (sotalol SmPC, AEMPS). Sotalol is not metabolised and is not expected to inhibit or induce cytochrome P450 enzymes (sotalol FDA label). The kidneys clear most dofetilide through glomerular filtration and active tubular secretion, and CYP3A4 metabolises only a small part of it (dofetilide FDA label). The documents do not describe any effect of one drug on the levels of the other.

Symptoms

QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Torsade de pointes causes palpitations, dizziness and fainting and, in rare cases, progresses to ventricular fibrillation (sotalol summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With sotalol, the incidence of torsade de pointes is dose-dependent, and torsade de pointes usually begins soon after the start of treatment or a dose increase (sotalol SmPC, AEMPS). In studies of people with supraventricular arrhythmias, torsade de pointes occurred in 0.8% of those taking dofetilide, mostly within the first three days of treatment (dofetilide label, US Food and Drug Administration, FDA). Sotalol also slows the heart rate and can cause atrioventricular block and heart failure with breathlessness and swelling. A slow heart rate itself raises the risk of torsade de pointes (sotalol SmPC, AEMPS, and sotalol FDA label).

Management

The combination is contraindicated. The Spanish sotalol summary of product characteristics (SmPC) contraindicates sotalol with class III antiarrhythmics that prolong the QT interval and names dofetilide explicitly (sotalol SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Dofetilide is not in the Spanish medicines register CIMA. According to the US sotalol label, stop class I and class III antiarrhythmics at least three half-lives before the first sotalol dose (sotalol label, US Food and Drug Administration, FDA). The US dofetilide label says to withdraw previous antiarrhythmic therapy under careful monitoring at least three plasma half-lives before the first dofetilide dose (dofetilide FDA label). The half-life of sotalol is 10–20 hours (sotalol SmPC, AEMPS) and that of dofetilide about 10 hours (dofetilide FDA label). Withdraw sotalol gradually over one to two weeks, especially in ischaemic heart disease (sotalol SmPC, AEMPS). Start dofetilide only in a facility that can provide creatinine clearance calculation, continuous electrocardiogram (ECG) monitoring and cardiac resuscitation for at least three days. Dofetilide is contraindicated if the QT or corrected QT interval (QTc) is above 440 ms (500 ms with ventricular conduction abnormalities) (dofetilide FDA label). Start sotalol in a facility with cardiac resuscitation and continuous ECG monitoring as well, after an ECG with QT measurement and an assessment of kidney function. Correct low potassium or magnesium before the first dose (sotalol SmPC, AEMPS, and sotalol FDA label). With dofetilide, keep potassium in the normal range before and during treatment (dofetilide FDA label). Stop dofetilide if the QTc or QT exceeds 500 ms (550 ms with ventricular conduction abnormalities) (dofetilide FDA label). If the QT reaches 500 ms or more during sotalol treatment, reduce the dose, lengthen the dosing interval or stop sotalol (sotalol FDA label).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dofetilide

Other interactions with Sotalol